After losing the battle for Allergan's control, Valeant Pharmaceuticals has announced a definitive agreement to acquire Salix Pharmaceuticals, which specializes in gastrointestinal drugs, for an enterprise value of about $14.5 billion
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.